ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

Launched by ERASMUS MEDICAL CENTER · Jan 21, 2022

Keywords

ClinConnect Summary

The START-TKI clinical trial is studying patients with non-small cell lung cancer (NSCLC) who are being treated with a specific type of treatment called tyrosine kinase inhibitors (TKIs). The main goal of the study is to collect blood samples from these patients over time to test for genetic changes (mutations) and to understand how the body processes these medications. This information may help doctors tailor treatments and improve outcomes for patients with this type of cancer.

To participate in this trial, you need to be at least 18 years old and have advanced or spreading NSCLC with a specific genetic mutation that can be treated with a TKI. You should also be able to understand the study and provide consent. Participants can expect to have regular blood draws during the study, but if you have difficulty giving blood, you may not be eligible. This trial is currently looking for participants, and your involvement could contribute to important research in lung cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Able to understand the written informed and able to give informed consent
• • Locally advanced or metastatic NSCLC with oncogenic driver mutation
• • Treatment with TKI according to standard of care
• Exclusion Criteria:
• • Unable to draw blood for study purposes